Top Page
CK Life Sciences International (Holdings), Inc.
(0775)
CK Life Sciences International (Holdings), Inc. (0775) vs. iShares MSCI Hong Kong ETF (EWH)
CK Life Sciences International (Holdings), Inc. Business Overview & Revenue Model
CK Life Sciences International (Holdings), Inc. Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 5.52B | 5.32B | 5.28B | 5.40B | 4.94B | Gross Profit |
| 1.69B | 1.64B | 1.63B | 1.63B | 1.41B | EBIT |
| 783.06M | 223.85M | 339.63M | 336.06M | 247.85M | EBITDA |
| 337.27M | 624.75M | 469.51M | 449.14M | 353.62M | Net Income Common Stockholders |
| -126.55M | 17.25M | 131.96M | 162.80M | 125.23M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 571.21M | 676.16M | 704.13M | 902.47M | 971.71M | Total Assets |
| 10.79B | 11.25B | 11.27B | 11.73B | 11.98B | Total Debt |
| 6.10B | 5.93B | 5.95B | 6.21B | 6.19B | Net Debt |
| 5.55B | 5.27B | 5.25B | 5.32B | 5.23B | Total Liabilities |
| 7.28B | 7.06B | 7.11B | 7.23B | 7.26B | Stockholders Equity |
| 3.51B | 4.19B | 4.16B | 4.50B | 4.72B |
| Cash Flow | Free Cash Flow | |||
| 154.06M | 222.35M | 146.69M | 206.33M | 151.12M | Operating Cash Flow |
| 353.53M | 514.18M | 363.66M | 423.57M | 530.96M | Investing Cash Flow |
| -96.64M | -67.96M | -22.12M | -257.88M | -457.31M | Financing Cash Flow |
| -341.98M | -477.95M | -515.34M | -220.08M | 168.74M |
CK Life Sciences International (Holdings), Inc. Technical Analysis
CK Life Sciences International (Holdings), Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $101.65B | 22.11 | 13.20% | 2.55% | -9.60% | -27.18% | |
72 Outperform | HK$991.98B | 6.84 | 7.49% | 11.71% | 37.04% | ||
66 Neutral | $98.90B | 52.12 | 6.14% | 1.09% | 7.63% | -24.23% | |
65 Neutral | HK$8.65B | ― | -3.29% | ― | 3.76% | -833.33% | |
56 Neutral | HK$59.66B | 251.27 | 0.42% | 0.56% | -2.06% | -83.44% | |
54 Neutral | $5.38B | 3.27 | -45.10% | 3.30% | 16.81% | 0.02% | |
53 Neutral | $5.16B | ― | -18.09% | 1.26% | -24.30% | -10350.00% |
CK Life Sciences International (Holdings), Inc. Corporate Events
CK Life Sciences International (Holdings) Inc. successfully conducted its Annual General Meeting on May 22, 2025, where all proposed resolutions were passed with overwhelming support. The resolutions included the approval of the audited financial statements for 2024, the election of directors, the appointment of auditors, and the granting of mandates to issue and buy back shares. This outcome reinforces the company’s governance structure and operational strategy, potentially strengthening its market position and shareholder confidence.
CK Life Sciences International (Holdings) Inc. has outlined the terms of reference for its Nomination Committee, which was established to ensure effective corporate governance in compliance with the Hong Kong Stock Exchange’s Listing Rules. The committee is responsible for reviewing the board’s structure and composition, identifying and recommending director candidates, assessing director independence, and supporting board performance evaluations. These measures are designed to align the board’s capabilities with the company’s strategic goals and enhance shareholder value.
CK Life Sciences International (Holdings) Inc. has outlined the terms of reference for its Audit Committee, which plays a crucial role in overseeing the company’s financial reporting, risk management, and internal control systems. The Audit Committee is composed of non-executive directors, with a majority being independent, and is tasked with ensuring compliance with corporate governance standards. This announcement underscores the company’s commitment to maintaining robust governance practices, which is vital for stakeholder confidence and the company’s operational integrity.
CK Life Sciences International (Holdings) Inc. announced its plans to present new data from preclinical studies of investigational cancer vaccines at the 2025 AACR Annual Meeting. The vaccines target proteins such as PRAME, PD-L1, B7-H3, and Claudin 6, which are associated with different cancers. The company is also making progress in developing an AI-powered platform to improve vaccine design. While the preclinical results are promising, the company has not yet commenced clinical trials, and stakeholders are advised to exercise caution.
CK Life Sciences International (Holdings) Inc. has announced its upcoming Annual General Meeting (AGM) scheduled for May 22, 2025, which will be held as a hybrid meeting both in-person and online. Key agenda items include the election of directors, appointment of auditors, and a resolution to grant the directors a mandate to issue additional shares, not exceeding ten percent of the current issued shares, with specific conditions on pricing and issuance period. This meeting is crucial for stakeholders as it will determine the company’s strategic directions and governance for the coming year.
CK Life Sciences International (Holdings) Inc. has announced promising preclinical results for its novel cancer vaccines targeting TROP2, a protein overexpressed in various aggressive cancers. The vaccines have shown impressive tumor growth inhibition in mice studies, particularly in breast and colorectal cancers, and the company aims to advance these vaccines into clinical trials. The potential commercialization of these vaccines could bring significant economic benefits, although clinical trials have not yet commenced, and patent approvals are pending.
CK Life Sciences International (Holdings), Inc. has announced a trading halt of its shares on the Hong Kong Stock Exchange as of April 10, 2025, pending a forthcoming announcement. This move indicates a significant development within the company, potentially impacting its market position and stakeholder interests.
CK Life Sciences International (Holdings) Inc. announced that it has restored its public float to above the minimum 25% threshold required by the Hong Kong Stock Exchange. This move ensures compliance with listing regulations and reflects the company’s commitment to maintaining transparency and shareholder value.
CK Life Sciences reported a loss of HK$126.6 million for 2024, primarily due to increased R&D investments and a decline in the fair value of its vineyard portfolio. The company is advancing its R&D efforts in non-opioid pain management solutions and therapeutic cancer vaccines, including a merger to form Dogwood Therapeutics for further development of Halneuron®. Additionally, CK Life Sciences is investing in liquid biopsy tests for early cancer detection, leveraging AI and cutting-edge technologies to enhance its cancer vaccine pipeline.
CK Life Sciences International (Holdings), Inc. has announced the composition of its Board of Directors and their respective roles and functions. The board includes a mix of executive and non-executive directors, with key figures such as LI Tzar Kuoi, Victor serving as Chairman, and KAM Hing Lam as President. The announcement also details the membership of various board committees, highlighting the company’s governance structure and commitment to oversight in areas such as audit, remuneration, nomination, sustainability, and executive management.